HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Profuse oral secretions after propafenone administration in neonates.

Abstract
Propafenone, an antiarrhythmic drug that is effective for treating supraventricular tachycardias, can induce well-known proarrhythmic and systemic adverse effects. We describe a previously unreported adverse effect in 3 newborns: oral propafenone-induced profuse oral secretions and respiratory distress of sufficient severity to necessitate discontinuation of propafenone.
AuthorsFiammetta Piersigilli, Cinzia Auriti, Massimo Stefano Silvetti, Gabriella Marrocco, Fabrizio Drago, Giulio Seganti
JournalThe Journal of pediatrics (J Pediatr) Vol. 157 Issue 5 Pg. 856-7 (Nov 2010) ISSN: 1097-6833 [Electronic] United States
PMID20659741 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2010 Mosby, Inc. All rights reserved.
Chemical References
  • Anti-Arrhythmia Agents
  • Propafenone
Topics
  • Anti-Arrhythmia Agents (adverse effects)
  • Bodily Secretions
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Mouth
  • Propafenone (adverse effects)
  • Respiratory Distress Syndrome, Newborn (chemically induced)
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: